Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies

Neurobiology of Disease

Volumn 78, Issue , 2015, Pages 162-171

  Bartus, R T ^a,g   Kordower, J H ^b   Johnson, E M ^c   Brown, L ^g   Kruegel, B R ^g   Chu, Y ^b   Baumann, T L ^d,g   Lang, A E ^e   Olanow, C W ^f   Herzog, C D ^g  

^a RTBioconsultants Inc   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ISIS PHARMACEUTICALS   (United States)

^e TORONTO WESTERN HOSPITAL   (Canada)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g Ceregene Inc   (United States)

Author keywords

AAV2; AAV2 antibodies (Ab); Alpha synuclein; Axonal transport deficiency; Gene therapy; Neurotrophic factors; Parkinson's disease; Synucleinopathies

Indexed keywords

ALPHA SYNUCLEIN; NEURTURIN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PARVOVIRUS VECTOR; TYROSINE 3 MONOOXYGENASE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; NERVE PROTEIN; NRTN PROTEIN, HUMAN; OLIG2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; AUTOPSY; BRAIN CORTEX; CASE REPORT; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; GLOBUS PALLIDUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; SHY DRAGER SYNDROME; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA; SUBSTANTIA NIGRA PARS RETICULATA; TISSUE DISTRIBUTION; VIRAL GENE THERAPY; CORPUS STRIATUM; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; METABOLISM; NERVE CELL; NERVE TRACT; NEURODEGENERATIVE DISEASES; PATHOLOGY; VIROLOGY;

AGED; ALPHA-SYNUCLEIN; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CORPUS STRIATUM; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MIDDLE AGED; NERVE TISSUE PROTEINS; NEURAL PATHWAYS; NEURODEGENERATIVE DISEASES; NEURONS; NEURTURIN; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84927921640     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.03.023     Document Type: Article

References (52)

1. Ai Y., Markesbery W., Zhang Z., Grondin R., Elseberry D., Gerhardt G.A. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J. Comp. Neurol. 2003, 461:250-261.
2. Aron L., Klein R. Repairing the parkinsonian brain with neurotrophic factors. Trends Neurosci. 2011, 34:88-100.
3. Auluck P.K., Caraveo G., Lindqist S. α-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu. Rev. Cell Dev. Biol. 2010, 26:211-233.
4. Bartus R.T. Translating the therapeutic potential of neurotrophic factors to clinical 'proof of concept': a personal saga achieving a career-long quest. Neurobiol. Dis. 2012, 48:153-178.
5. Bartus R.T. CERE-120 (AAV2-NRTN) for the treatment of Parkinson's disease: experience from 4 clinical trials and human autopsy data. Proceedings of the 16th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT), Salt Lake City, UT 2013, (May 17).
6. Bartus R.T., Herzog C.D., Chu Y., Wilson A., Brown L., Siffert J., et al. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov. Disord. 2011, 26:27-36.
7. Bartus R.T., Baumann T.L., Brown L., Kruegel B.R., Ostrove J.M., Herzog C.D. Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease. Neurobiol. Aging 2013, 34:35-61.
8. Bartus R.T., Weinbert M.S., Samulski R.J. Parkinson's disease gene therapy: success by design meets failure by efficacy. Mol. Ther. 2014, 22:487-497.
9. Braak H., Sandmann-Keil D., Gai W., Braak E. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry. Neurosci. Lett. 1999, 265:67-69.
10. Chu Y., Kordower J.H. Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease?. Neurobiol. Dis. 2007, 25:134-149.
11. Chu Y., Morfini G.A., Langhamer L.B., He Y., Brady S.T., Kordower J.H. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain 2012, 135:2058-2073.
12. Chung C.Y., Koprich J.B., Siddiqi H., Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci. 2009, 29:3365-3373.
13. De Vos K.J., Grierson A.J., Ackerley S., Miller C.C. Role of axonal transport in neurodegenerative diseases. Annu. Rev. Neurosci. 2008, 31:151-173.
14. Decressac M., Ulusoy A., Mattsson B., Georgievska B., Romero-Ramos M., Kirik D., et al. GDNF fails to exert neuroprotection in a rat alpha-synuclein model of Parkinson's disease. Brain 2011, 134:2302-2311.
15. Decressac M., Kadkhodaei B., Mattsson B., Laguna A., Perlmann T., Bjorklund A. Alpha-synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci. Transl. Med. 2012, 4:163ra156.
16. Decressac M., Mattsson B., Bjorklund A. Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinson's disease. Exp. Neurol. 2012, 235:306-315.
17. Eriksdotter Jonhagen M., Nordberg A., Amberla K., Backman L., Ebendal T., Meyerson B., et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 1998, 9:246-257.
18. Gasmi M., Herzog C.D., Brandon E.P., Cunningham J.J., Ramirez G.A., Ketchum E.T., et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's Disease. Mol. Ther. 2007, 15:62-68.
19. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003, 9:589-595.
20. Herzog C.D., Dass B., Holden J.E., Stansell J., Gasmi M., Tuszynski M.H., et al. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov. Disord. 2007, 22:1124-1132.
21. Herzog C.D., Dass B., Gasmi M., et al. Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol. Ther. 2008, 16(10):1737-1744.
22. Herzog C.D., Brown L., Gammon D., et al. Expression, bioactivity, and safety 1year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery 2009, 64(4):602-612.
23. Herzog C.D., Bishop K., Brown L., Wilson A., Kordower J.H., Bartus R.T. Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically-active neurotrophic factor proteins for neurodegenerative diseases. Drug Deliv. Transl. Res. 2011, 1:361-382.
24. Horger B.A., Nishimura M.C., Armanini M.P., Wang L.C., Poulsen K.T., Rosenblad C., et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J. Neurosci. 1998, 18:4929-4937.
25. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 2002, 22:2780-2791.
26. Kordower J.H., Palfi S., Chen E.Y., Ma S.Y., Sendera T., Cochran E.J., et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 1999, 46:419-424.
27. Kordower J.H., Herzog C.D., Dass B., Bakay R.A., Stansell J., Gasmi M., et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann. Neurol. 2006, 60:706-715.
28. Kordower J.H., Olanow C.W., Dodiya H.B., Chu Y., Beach T.G., Adler C.H., Halliday G.M., Bartus R.T. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013, 136:2419-2431.
29. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 2006, 59:459-466.
30. Lo Bianco C., Ridet J.L., Schneider B.L., Deglon N., Aebischer P. Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10813-10818.
31. Lo Bianco C., Deglon N., Pralong W., Aebischer P. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiol. Dis. 2004, 17:283-289.
32. Love S., Plaha P., Patel N.K., Hotton G.R., Brooks D.J., Gill S.S. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat. Med. 2005, 11:703-704.
33. Marks W.J., Ostrem J.L., Verhagen L., Starr P.A., Larson P.S., Bakay R.A., et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 2008, 7:400-408.
34. Marks W.J., Bartus R.T., Siffert J., Davis C.S., Lozano A., Boulis N., et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010, 9:1164-1172.
35. Mittermeyer G., Christine C.W., Rosenbluth K.H., Baker S.L., Starr P., Larson P., et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum. Gene Ther. 2012, 23:377-381.
36. Morfini G.A., Burns M., Binder L.I., Kanaan N.M., LaPointe N., Bosco D.A., et al. Axonal transport defects in neurodegenerative diseases. J. Neurosci. 2009, 29:12776-12786.
37. Mufson E.J., Kroin J.S., Sendera T.J., Sobreviela T. Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog. Neurobiol. 1999, 57:451-484.
38. Nutt J.G., Burchiel K.J., Comella C.L., Jankovic J., Lang A.E., Laws E.R., et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, 60:69-73.
39. Olanow C.W., Bartus R.T., Baumann T., et al. Neurturin gene delivery in Parkinson's disease: a double-blind controlled trial. Ann. Neurol. 2015, (submitted for publication).
40. O'Malley K.L. The role of axonopathy in Parkinson's disease. Exp. Neurobiol. 2010, 19:115-119.
41. Penn R.D., Kroin J.S., York M.M., Cedarbaum J.M. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). Neurosurgery 1997, 40:94-99. (discussion 99-100).
42. Peterson A.L., Nutt J.G. Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 2008, 5:270-280.
43. Raff M.C., Whitmore A.V., Finn J.T. Axonal self-destruction and neurodegeneration. Science 2002, 296:868-871.
44. Rafii M.S., Baumann T.L., Bakay R.A., Ostrove J.M., Siffert J., Dleisher A.S., Herzog C.H., Barba D., Pay M., Salmon D.P., Chu Y., Kordower J.H., Bishop K., Keator D., Potkin S., Bartus R.T. A phase 2 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimer's Dement. 2014, 10.1016/j.jalz.2013.09.004.
45. Roy S., Zhang B., Lee V.M., Trojanowski J.Q. Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol. 2005, 109:5-13.
46. Salvatore M.F., Ai Y., Fischer B., Zhang A.M., Grondin R.C., Zhang Z., et al. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp. Neurol. 2006, 202:497-505.
47. Scott D.A., Tabarean I., Tang Y., Cartier A., Masliah E., Roy S. A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J. Neurosci. 2010, 30:8083-8095.
48. Sherer T.B., Fiske B.K., Svendsen C.N., Lang A.E., Langston J.W. Crossroads in GDNF therapy for Parkinson's disease. Mov. Disord. 2006, 21:136-141.
49. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 2005, 102:216-222.
50. Sulzer D. Clues to how alpha-synuclein damages neurons in Parkinson's disease. Mov. Disord. 2010, 25(Suppl. 1):S27-S31.
51. Tuszynski M.H., Thal L., Pay M., Salmon DP U.H.S., Bakay R.A., et al. A phase I clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 2005, 1-5.
52. Walker D.G., Beach T.G., Xu R., Lile J., Beck K.D., McGeer E.G., et al. Expression of the proto-oncogene Ret, a component of the GDNF receptor complex, persists in human substantia nigra neurons in Parkinson's disease. Brain Res. 1998, 792:207-217.